Clinical Trials Logo

Acral Lentiginous Melanoma clinical trials

View clinical trials related to Acral Lentiginous Melanoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03698019 Active, not recruiting - Clinical trials for Clinical Stage IV Cutaneous Melanoma AJCC v8

A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

Start date: February 15, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high-risk melanoma. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab before and after surgery may work better compared to after surgery alone in treating melanoma.

NCT ID: NCT03025256 Active, not recruiting - Metastatic Melanoma Clinical Trials

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

Start date: May 2, 2018
Phase: Phase 1
Study type: Interventional

This phase I/Ib trial studies the side effects and best dose of intrathecal nivolumab, and how well it works in combination with intravenous nivolumab in treating patients with leptomeningeal disease. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT00937937 Active, not recruiting - Recurrent Melanoma Clinical Trials

Dinaciclib in Treating Patients With Stage IV Melanoma

Start date: July 1, 2009
Phase: Phase 2
Study type: Interventional

This phase II trial is studying the side effects and how well dinaciclib works in treating patients with stage IV melanoma. Dinaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00424515 Active, not recruiting - Mucosal Melanoma Clinical Trials

Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma

BUS255
Start date: July 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate how effective Imatinib (Gleevec) is in treating acral lentiginous and mucosal melanoma which has spread to other parts of the body in patients who's disease carries a c-kit mutation. Gleevec is a protein-kinase inhibitor. It is believed that Gleevec may be effective in blocking signals on certain cancer cells which allow the malignant cells to multiply and spread.